Shenzhen Hepalink Pharmaceutical Group Co., Ltd. provided consolidated earnings guidance for the year ended December 31, 2022. For the year ending December 31, 2022, the company expects net profit attributable to shareholders of the listed company of RMB 617.00 million to RMB 773.00 million, increase as compared with the corresponding period: 156.24% to 221.03% and basic earnings per share of RMB 0.4205 per share to RMB 0.5268 per share.